Intellectual Property

We have an exclusive license to a patent portfolio created by the original developers of our alphavirus vector technology, the University of North Carolina at Chapel Hill and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). In addition, we are aggressively pursuing further patent protection as we discover new improvements to develop and implement the technology's full potential.

Our alphavaccine technology is the subject of 16 issued U.S. patents and foreign counterparts. In addition, ten application families are pending and there is an active pipeline of ongoing improvements.

Issued US Patents:

5,185,440	cDNA Clone Coding for VEE Virus and Attenuating Mutations Thereof
5,505,947	Attenuating Mutations in Venezuelan Equine Encephalitis Virus
5,639,650	cDNA Clone for South African Arbovirus No. 86
5,643,576	Method of Inducing an Immune Response with a Live VEE Virus Expressing a Heterologous Immunogen
5,792,462	Alphavirus RNA Replicon Systems
5,811,407	In vivo Delivery and Expression of Heterologous Genes in the Bone Marrow
6,008,035	In vivo Delivery and Expression of Heterologous Genes in the Bone Marrow
6,156,558	Alphavirus RNA Replicon Systems
6,521,235	Alphavirus RNA Replicon Systems
6,531,135	Alphavirus RNA Replicon Systems
6,541,010	Alphavirus RNA Replicon Systems
6,583,121	In vivo Delivery and Expression of Heterologous Genes in the Bone Marrow
6,783,939	Alphavirus Vectors and Virosomes with Modified HIV Genes for Use in Vaccines
6,844,188	Methods and Modified Cells for the Treatment of Cancer
6,982,087	Vectors derived from South African Arbovirus No. 86
7,045,335	Alphavirus replicon vector systems
7,078,218	Alphavirus particles and methods for preparation
7,235,235	Alphavirus RNA replicon systems